COO — The Cooper Companies, Inc.

Summary of Cooper Companies Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Consolidated Revenue: $1.024 billion, up 6.2% year-over-year (2.9% organic growth).
• CooperVision Revenue: $695 million, up 7.6% (3.3% organic growth).
• CooperSurgical Revenue: $329 million, up 3.3% (2.2% organic growth).
• Operating Margin: Improved to 26.9%, with operating income up 13.9%.
• Non-GAAP EPS: Grew 20% to $1.10.
• Free Cash Flow: Strong at $159 million.
• Debt: Reduced net debt to $2.4 billion; amended and extended $950 million of term loan to February 2031.

2. Strategic Updates and Business Highlights

• Market Share Gains: CooperVision gained share for the 18th consecutive year in 2025, with a focus on premium MyDay daily silicone hydrogel portfolio.
• Product Launches: Successful launches of MyDay MiSight in EMEA and Japan, with strong early adoption.
• Operational Excellence: Organizational changes and IT implementations are yielding synergies, allowing for increased investment in sales and marketing.
• Capital Allocation: Continued commitment to share repurchases ($92 million in Q1) and debt reduction, with a disciplined approach to capital deployment.

3. Forward Guidance and Outlook

• Revenue Guidance: Consolidated revenues expected between $4.3 billion and $4.35 billion for FY 2026, with organic growth of 4.5% to 5.5%.
• Earnings Guidance: Raised to $4.58 to $4.66 per share.
• Free Cash Flow Outlook: Increased to $600 million to $625 million for FY 2026.
• Market Expectations: Anticipate a stronger Q2, with CooperSurgical expected to improve sequentially.

4. Bad News, Challenges, or Points of Concern

• Asia Pacific Performance: Region declined 4% due to softness in Japan, particularly with older hydrogel products. Expected to remain down in Q2 but projected to improve in Q3.
• Middle East Risks: Ongoing geopolitical issues could impact fertility business, although overall exposure is limited (about 2% of sales).
• Competitive Pressures: Concerns about potential impacts from competitors, particularly in the fertility market with the introduction of new products.

5. Notable Q&A Insights

• Market Dynamics: Al White noted that the contact lens market is stabilizing, with positive pricing dynamics and a potential rebound in growth.
• Private Label Contracts: New contracts are expected to contribute positively to revenue, although there may be slight pressure on gross margins.
• Myopia Control: The launch of MyDay MiSight is expected to drive significant growth, with strong early reception in Japan and EMEA.
• Operational Efficiency: The company is leveraging AI and technology to enhance operational efficiency and improve margins, which is expected to continue throughout the year.

Overall, Cooper Companies reported a strong start to FY 2026, with solid financial performance and strategic initiatives aimed at sustaining growth, despite facing challenges in specific regions and competitive pressures.